4.5 Article

A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy

期刊

HEART
卷 98, 期 8, 页码 625-630

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/heartjnl-2011-300368

关键词

-

资金

  1. University of Sydney
  2. National Health and Medical Research Council (NHMRC)

向作者/读者索取更多资源

Background Traditional management of families with hypertrophic cardiomyopathy (HCM) involves periodic lifetime clinical screening of family members, an approach that does not identify all gene carriers owing to incomplete penetrance and significant clinical heterogeneity. Limitations in availability and cost have meant genetic testing is not part of routine clinical management for many HCM families. Objective To determine the cost-effectiveness of the addition of genetic testing to HCM family management, compared with clinical screening alone. Methods A probabilistic Markov decision model was used to determine cost per quality-adjusted life-year and cost for each life-year gained when genetic testing is included in the management of Australian families with HCM, compared with the conventional approach of periodic clinical screening alone. Results The incremental cost-effectiveness ratio (ICER) was $A785 (510 pound or is an element of 587) per quality-adjusted life-year gained, and $A12 720 (8261 pound or is an element of 9509) per additional life-year gained making genetic testing a very cost-effective strategy. Sensitivity analyses showed that the cost of proband genetic testing was an important variable. As the cost of proband genetic testing decreased, the ICER decreased and was cost saving when the cost fell below $A248 (161 pound or is an element of 185). In addition, the mutation identification rate was also important in reducing the overall ICER, although even at the upper limits, the ICER still fell well within accepted willingness to pay bounds. Conclusions The addition of genetic testing to the management of HCM families is cost-effective in comparison with the conventional approach of regular clinical screening. This has important implications for the evaluation of families with HCM, and suggests that all should have access to specialised cardiac genetic clinics that can offer genetic testing.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据